CA Patent

CA2722177C — 1'-substituted carba-nucleoside analogs for antiviral treatment

Assigned to Gilead Sciences Inc · Expires 2016-08-16 · 10y expired

What this patent protects

Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides of Formula (I), nucleoside phosphates and prodrugs thereof, wherein the l' position of the nucleoside sugar is subst…

USPTO Abstract

Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides of Formula (I), nucleoside phosphates and prodrugs thereof, wherein the l' position of the nucleoside sugar is substituted, and wherein each of X1 or X2 is independently C-R10 or N. The compounds, compositions, and methods provided may be useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections. (see formula I)

Drugs covered by this patent

Patent Metadata

Patent number
CA2722177C
Jurisdiction
CA
Classification
—
Expires
2016-08-16
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.